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Catamenial epilepsy is a type of refractory epilepsy characterized by seizure clusters
around perimenstrual or periovulatory period. The pathophysiology of catamenial
epilepsy still remains unclear, yet there are few animal models to study this gender-
specific disorder. The pathophysiology of perimenstrual catamenial epilepsy involves the
withdrawal of the progesterone-derived GABAergic neurosteroids due to the decline in
progesterone level at the time of menstruation. These manifestations can be faithfully
reproduced in rodents by specific neuroendocrine manipulations. Since mice and rats,
like humans, have ovarian cycles with circulating hormones, they appear to be suitable
animal models for studies of perimenstrual seizures. Recently, we created specific
experimental models to mimic perimenstrual seizures. Studies in rat and mouse models
of catamenial epilepsy show enhanced susceptibility to seizures or increased seizure
exacerbations following neurosteroid withdrawal. During such a seizure exacerbation
period, there is a striking decrease in the anticonvulsant effect of commonly prescribed
antiepileptics, such as benzodiazepines, but an increase in the anticonvulsant potency
of exogenous neurosteroids. We discovered an extrasynaptic molecular mechanism
of catamenial epilepsy. In essence, extrasynaptic δGABA-A receptors are upregulated
during perimenstrual-like neuroendocrine milieu. Consequently, there is enhanced
antiseizure efficacy of neurosteroids in catamenial models because δGABA-A receptors
confer neurosteroid sensitivity and greater seizure protection. Molecular mechanisms
such as these offer a strong rationale for the clinical development of a neurosteroid
replacement therapy for catamenial epilepsy.
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INTRODUCTION
Catamenial epilepsy is a gender-specific epilepsy condition that is typified by the
occurrence of seizure exacerbations in a cyclical pattern during particular phases of
women’s menstrual cycles (Newmark and Penry, 1980; Reddy, 2004; Herzog et al., 2008).
It appears that both partial and primary generalized epilepsies have been known to exhibit
these cyclical fluctuations (Reddy, 2004). Since antiquity, it has been recognized that
seizure susceptibility is greatly influenced by the menstrual cycle. In some cases, women
diagnosed with an epileptic disorder that demonstrates changes in seizure frequency in
a cyclical manner are routinely treated with antiepileptic drugs (AEDs) for which the
seizures do not respond. In these cases, catamenial epilepsy is categorized as a specific
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form of pharmacoresistant epilepsy (Reddy and Rogawski, 2009).
Most of these patients suffer from uncontrollable catamenial
seizures, which could damage the brain and adversely impact
their quality of life.
Catamenial seizure exacerbations affect 10–70% of women
with epilepsy, many of these women being of reproductive age
(Reddy, 2009). The large disparity in incidence is primarily
due to differences in definition. Three types of catamenial
seizures have been identified: Perimenstrual (C1), Periovulatory
(C2), and Inadequate luteal-phase (C3) (Herzog et al., 1997;
Reddy, 2014) (Figure 1). A specific pattern can be identified
by charting menses and tallying seizures in a diary format, in
addition to procuring a mid-luteal phase serum progesterone
level to differentiate between normal and deficient luteal phases
(Herzog et al., 2008; Quigg et al., 2009). The menstrual cycle
is divided into four phases: (a) menstrual phase; (b) follicular
phase; (c) ovulatory phase; and (d) luteal phase (Figure 1). The
number of seizures is recorded, by phase, for a time period
of no less than two menstrual cycles. Catamenial epilepsy can
be diagnosed in women with both ovulatory and anovulatory
cycles, in fact one study found that 16.5% of catamenial epilepsy
patients had anovulatory cycles (Herzog et al., 2004). These
women were found to show inadequate luteal phase (C3) or
anovulatory luteal seizures which is the third type of catamenial
epilepsy. By performing a complete review of menstruation
patterns and seizure diaries along with the evaluation of
serum progesterone levels, a diagnosis of catamenial epilepsy
can be made because an increase in frequency of twofold
or larger during one specific phase of the menstrual cycle
is indicative of a problem (Reddy, 2009). The perimenstrual
type is more common than other two types of catamenial
epilepsy.
Experimental models have been developed that mimic
perimenstrual seizures (i.e., catamenial epilepsy). This seizure
condition can be induced either by electrical stimulation or
with pharmacologic agents in rodents with suitable manipulation
of neuroendocrine milieu (Reddy, 2009; Reddy et al., 2012).
This review provides a brief overview of different experimental
models of catamenial epilepsy for studies of new therapeutic
strategies. It also describes our recent findings of an extrasynaptic
molecular mechanism of catamenial epilepsy and its clinical
potential for designing a rational therapeutic strategy. There
are several features for an ideal catamenial epilepsy model
(Table 1). An ideal animal model of epilepsy should reflect a
pathophysiology akin to those of catamenial seizures in women
with epilepsy. Human epilepsy is an intricate and complex brain
disorder which encompasses a myriad of causes and seizure
phenotypes, thus it is extremely doubtful that any single animal
model can truly recapitulate the full spectrum of catamenial
seizure features. Therefore, it is necessary to test the drug
products and pathological mechanisms in a battery of animal
models.
FIGURE 1 | The neuroendocrine basis of catamenial seizures during menstrual cycle. The upper panel illustrates temporal occurrence of catamenial
seizures and shows a strong relationship between seizure frequency and estradiol/progesterone levels. The lower panel illustrates the three types of catamenial
epilepsy. The vertical pink bars (left and right) represent the likely period for the perimenstrual (C1) type, while the vertical pink bar (middle) represents the likely period
for the periovulatory (C2) type. The horizontal dark gray bar (bottom) represents the inadequate luteal (C3) type, which typified by low level of progesterone and
progesterone-derived neurosteroid allopregnanolone (AP) (Adapted from Reddy, 2014).
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TABLE 1 | Desirable features of animal model of catamenial epilepsy.
• Exhibit appropriate menstrual seizure phenotype
• Consistent with the neuroendocrine features of women with epilepsy
• Exhibit appropriate latency following steroid hormone fluctuation
• Show perimenstrual acute hyperexcitability and neuronal plasticity
• Express catamenial seizures following progesterone/neurosteroid withdrawal
period
• Respond to drug therapy and exhibit resistance to certain anticonvulsants
• Allow rapid screening of novel compounds
AN OVERVIEW OF NEUROENDOCRINE
BASIS OF CATAMENIAL EPILEPSY
Catamenial epilepsy is a multidimensional neurological disorder
ascribed to a variety of origins (Reddy, 2013a–c). Epilepsy
usually develops because of a genetic defect or after brain injury.
Since there is no definitive evidence of genetic components,
catamenial epilepsy is assumed to be an acquired disorder in
many cases. A battery of mechanisms have been proposed as
causes for catamenial epilepsy including: physiological variation
in ovarian hormone secretion, fluctuations in water and
electrolyte balance, and changes in AED levels (Scharfman and
MacLusky, 2006; Reddy, 2009; Pack et al., 2011). The changes
in the levels of steroid hormones circulating throughout the
central nervous system are involved in the development of this
epileptic condition (Figure 1). The role of estrogens in seizure
susceptibility is complex; however, it is suggested that estrogen
plays a role in facilitating some forms of catamenial seizures
including periovulatory type (Logothetis et al., 1959; Bäckström,
1976; Bäckström et al., 1984; Bonuccelli et al., 1989; Edwards
et al., 1999). The estrogens are widely recognized to cause
proconvulsant effects (Reddy, 2009; Younus and Reddy, 2016).
The periovulatory catamenial activities have been attributed to
mid-cycle surges of estrogen which are generally unhindered by
progesterone except in the early stages of the luteal phase.
Progesterone has powerful antiseizure effects in both animals
and humans, and plays a critical role in the pathophysiology
of catamenial epilepsy (Jacono and Robinson, 1987; Herzog,
1999; Reddy, 2009; Reddy and Jian, 2010). It has anticonvulsant
activity in a variety of seizure models (Reddy et al., 2004).
Natural cyclical fluctuations of progesterone during the
menstrual cycle can influence catamenial seizure susceptibility
in women with epilepsy (Figure 1). In this case, a decrease
in seizures is seen during the mid-luteal phase, when serum
progesterone levels are elevated, and an increase in seizures is
seen during the premenstrual phase when progesterone levels
fall. Changes in progesterone levels have been directly correlated
with catamenial seizures. Progesterone is a key intermediate
precursor for the synthesis of many neurosteroids in the brain.
Neurosteroids are highly lipophilic steroid compounds that
can rapidly modify the excitability of neurons through non-
genomic mechanisms (Reddy, 2003). Numerous neurosteroids
are shown to be biosynthesized within the brain (Agís-Balboa
et al., 2006), the most widely studied being allopregnanolone
(AP), allotetrahydrodeoxycorticosterone (THDOC), and
androstanediol. In addition, because neuro-steroids easily cross
the blood–brain barrier, even if they are thus neurosteroids
synthesized peripherally, they tend to build up in the brain
(Mellon et al., 2001; Do Rego et al., 2009; Reddy, 2010).
The mechanism by which neurosteroids are able to rapidly
alter neuronal excitability is through reversible interaction
with synaptic and extrasynaptic GABA-A receptors. AP and
similar neurosteroids are allosteric agonists that directly activate
GABA-A receptors (Carver and Reddy, 2013). The mechanism
of action is concentration dependent; at higher concentrations
they directly activate the receptor whereas, at low concentrations
neurosteroids potentiate GABA-gated currents. The GABA-A
receptor consists of five subunits that form a chloride channel.
So far, sixteen subunits have been identified (α1–6, β1–3,
γ1–3, δ,ε,θ, and pi subunits). Neurosteroids bind to distinct sites
within the α- and β-subunits (Akk et al., 2005; Hosie et al.,
2007; Chisari et al., 2010). The GABA-A receptor mediates
both phasic inhibition (via synaptic) and tonic inhibition (via
peri or extrasynaptic receptors) (Brickley and Mody, 2012).
Neurosteroids can work on all receptor isoforms; however,
they have a particular effect on the extrasynaptic δ-subunit
GABA-A receptors which regulate tonic inhibition (Wohlfarth
et al., 2002; Carver and Reddy, 2013; Carver et al., 2014).
Thus, GABA-A receptors containing δ-subunits are greatly
sensitive to neurosteroid potentiation. Tonic currents cause
a shunting inhibition of neuronal networks thereby greatly
reducing excitability. However, such extrasynaptic receptors are
extremely insensitive to modulation by benzodiazepines (Reddy
et al., 2015).
Neurosteroids are robust anticonvulsants that are efficacious
for seizures induced by GABA-A receptor antagonists (Reddy,
2011). Neurosteroids have also been effective against pilocarpine-
induced limbic seizures and kindling-induced seizures in animal
models; however, neurosteroids have shown little effect or
are only weakly active against seizures elicited by maximal
electroshock (Kokate et al., 1994; Reddy and Rogawski, 2000a,b,
2002, 2010; Reddy, 2004, 2011). Additionally, neurosteroids
have been highly effective in controlling seizures due to
drug withdrawal, including ethanol and cocaine (Reddy and
Woodward, 2004). In contrast to benzodiazepines, chronic
exposure to neurosteroids does not lead to a tolerance
of anticonvulsant activity (Reddy and Rogawski, 2000a).
There is an increasing amount of evidence suggesting that
endogenous neurosteroids play an important role in regulating
epileptogenesis, in addition to the anticonvulsant activity of these
compounds (Reddy et al., 2010; Reddy and Mohan, 2011).
In women diagnosed with epilepsy, it has been shown
that both endogenous neurosteroids and plasticity in GABA-A
receptor subunits may be factors in perimenstrual catamenial
seizure susceptibility (Reddy, 2014). Seizure control can be lost
when neurosteroid levels fluctuate (Herzog and Frye, 2003). Even
in women with a normal menstrual cycle, neurosteroids have
been associated in perimenstrual seizure exacerbations. This has
led to some hypotheses that the withdrawal of progesterone-
derived neurosteroids leads to enhanced excitability (Smith et al.,
2007). Strong evidence has been reported that shows ovarian
cycle-linked fluctuations in neurosteroids modulate GABA-A
receptor plasticity. We reported that neurosteroid withdrawal
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(NSW) upregulates the expression of the α4 and δ-subunits in
the hippocampus (Gangisetty and Reddy, 2010; Wu et al., 2013;
Carver et al., 2014). Such subunit plasticity is also noted in other
withdrawal models (Smith et al., 1998b; Gulinello et al., 2001;
Maguire et al., 2005; Maguire and Mody, 2007).
MOLECULAR INSIGHTS ON
NEUROSTEROID WITHDRAWAL
Neuronal GABA-A receptors undergo cyclical variations in
women. GABA-A receptor subunit expression is not static either,
but undergoes alterations which compensate for fluctuations
and changes in endogenous hormonal levels and exogenously
administered agents which modulate GABA-A receptors, such
as neurosteroids or benzodiazepines. Extended exposure to AP
in rats causes upregulation of the α4-subunit in hippocampus
resulting in a decreased sensitivity to benzodiazepine (Smith
et al., 1998a,b; Gangisetty and Reddy, 2010). The α4 subunit
preferentially co-assembles with δ, rather than γ2, to form
extrasynaptic GABA-A receptors. Increases in the expression
of the δ-subunit within the hippocampus can be seen as a
result of AP administration. Additionally, the tolerance of
benzodiazepines can increase at these tonic currents, creating a
heightened insensitivity to these compounds. Higher δ-subunit
expression has been reported after exposure to progesterone,
presumably caused by the conversion of progesterone to AP.
The exact link between α4-subunit plasticity and excitability
is unclear. The normally low prevalence of the α4-subunit into
synaptic GABA-A receptors generates synaptic currents with
accelerated decay kinetics, causing an overall decrease in charge
transfer, which likely results in reduced inhibition. Neurosteroids
that modulate GABA-A receptors produce a prolongation of the
decay of GABA-mediated synaptic currents. Hence, during the
luteal phase when there are elevated levels of AP, the acceleration
due to α4-substitution is balanced. However, when the levels fall
during menstruation, the synaptic inhibition is greatly reduced,
causing heightened excitability that predisposes one to seizures,
along with other effects.
Upregulation of α4 has been linked to a compensatory
reduction in α1 expression. Some research has suggested that
removal of neurosteroids is related to a downregulation in α1
and γ2 subunit expression (see Reddy and Rogawski, 2009). It
is known that the γ2 subunit is necessary for synaptic clustering
and targeting of GABA-A receptors in dendrites. Heightened
excitability might be the outcome of a net reduction of synaptic
GABA-A receptors. It is important to note that if exposure to
neurosteroids exceeds 72 h, then there is a return of α4-subunit
expression to normal levels, indicating that the rise in α4-subunit
expression is temporary. However, if there are extended periods
of neurosteroid exposure, then withdrawal causes a powerful
rebound rise in α4-subunit expression. It is the withdrawal of
neurosteroids near the beginning of menstruation, instead of the
extended exposure to neurosteroids during the luteal phase that
is probably to be most pertinent to the enhanced excitability
and greater seizure susceptibility in perimenstrual catamenial
epilepsy (Smith et al., 2007; Carver et al., 2014). Chronic
exposure to neurosteroids is correlated by the downregulation of
δ-subunit expression and extrasynaptic GABA-A receptors. This
alteration is suspected to be a compensatory mechanism, to avoid
extreme sedation resulting from elevated neurosteroid levels
acting on sensitive δ-containing GABA-A receptors (Maguire
and Mody, 2007). When there is a withdrawal of neurosteroids,
δ-expression quickly recovers and there is striking upregulation
following perimenstrual-like condition (Carver et al., 2014).
When recovery does not occur quickly enough, there is the
possibility of an enhancement of excitability because of a
reduction in tonic inhibition mediated by extrasynaptic GABA-A
receptors in the comparative absence of neurosteroids.
CURRENT ANIMAL MODELS OF
CATAMENIAL EPILEPSY
Animal models of epilepsy continue to play an important
role to better understand the pathophysiology and discovery
of new AEDs. Traditional seizure models were established by
acutely inducing seizures in naïve animals. These models are
not appropriate for catamenial epilepsy because they do not
provide the correct avenue to test specific therapies targeted
to the disorder. The models of catamenial epilepsy are clearly
different from induction models utilizing pilocarpine, chronic
kainic acid, or hippocampal kindling because they create
extreme damage and a remodeling response in the brain, thus
resulting in recurrent seizures. Generally, catamenial epilepsy
models should be characterized to specifically mimic alterations
in seizure vulnerability caused by menstruation and ovarian
hormone fluctuations (Reddy, 2009). During the luteal phase of
menstruation in humans, levels of circulating progesterone are
elevated for 10–12 days prior to declining. These phenomena can
be faithfully reproduced in rodents with specific neuroendocrine
manipulations. Because mice and rats, like humans, have ovarian
cycle with circulating hormones, they appear to be suitable
animal models for studies of perimenstrual seizures.
Three broad categories of models have been described in
animals that partially simulate the pattern of catamenial seizures
(Reddy, 2009). For the first category, study protocols focus on
the luteal phase. The mimicry is created by the induction of
prolonged elevated levels of progesterone and estrogens then
creating a sudden fall to imitate menstruation in rodents. These
categories of models have been named: (a) pseudopregnancy,
(b) chronic progesterone, and (c) progesterone (neurosteroid)
withdrawal (Moran and Smith, 1998; Smith et al., 1998a; Reddy
et al., 2001). The second category is built on the concept
of the normal estrous cycle; sometimes this model requires
administrating exogenous hormones that replicate the stages of
the estrous cycle in ovariectomized rodents (Frye and Bayon,
1998; Wu et al., 2013). These functional models are closer
to recreating the typical ovarian cycle and are therefore more
comparable models. Finally, the third category consists of
utilizing epileptic animals and exposing them to both steroid
hormones and NSW. The severity and frequency of spontaneous
seizures are the primary endpoints to evaluate the exacerbation
of catamenial-like seizure (Reddy and Zeng, 2007; Reddy, 2013a).
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BOX 1 | Rat catamenial epilepsy models.
(1) The pseudopregnancy model. Approach: It was the first model of perimenstrual catamenial epilepsy utilizing the concept of pseudopregnancy (Reddy et al.,
2001). In this model, a state of persistently elevated progesterone in female rats was induced by pseudopregnancy and the augmented neurosteroid levels including
AP were abruptly withdrawn by blocking its synthesis using the 5α-reductase inhibitor finasteride. It was based on the hypothesis that increased susceptibility of
catamenial seizure is caused by an abrupt decline (“withdrawal”) in circulating levels of progesterone and, consequently, of levels of its metabolite AP in the brain.
Method: In this model, a persistently elevated level of progesterone in young female rats was induced by a standard gonadotropin regimen (Figure 3A). On day 11,
animals are treated with finasteride to trigger “neurosteroid withdrawal.” Acute seizure testing was performed on the day following finasteride (day 12). The drop in
AP levels following finasteride treatment was significant (Figure 2). Acute withdrawal of AP resulted in an increase in seizure susceptibility to pentylenetetrazol, but
long-term treatment with finasteride did not, mimicking the situation in catamenial epilepsy. In another model, withdrawal of progesterone (neurosteroid) was obtained
by ovariectomy (Moran and Smith, 1998). This model was associated with decreased seizure threshold to picrotoxin and reduced sensitivity to benzodiazepines. The
progesterone withdrawal-induced hyperexcitability fits well an increase in seizure susceptibility in rodents (Voiculescu et al., 1994; Frye and Bayon, 1998) and also
with clinical perimenstrual seizure patterns (Herzog et al., 1997).
(2) The exogenous progesterone model. Approach: This model is based on direct progesterone administration for extended periods using silastic implants
or multiple daily injections, and then cessation of progesterone for inducing withdrawal (Smith et al., 1998a). Method: There are many methods in which steroid
progesterone was administered for extended periods including silastic implants or multiple daily injections (Costa et al., 1995; Moran and Smith, 1998; Smith et al.,
1998a). These models mimic the high P levels found during luteal phase of the menstrual cycle. Withdrawal of progesterone containing implants or cessation of
chronic progesterone treatment induces an abrupt decline of progesterone levels that could simulate the hormonal milieu of menstruation. Akin to finasteride-induced
neurosteroid withdrawal, withdrawal of progesterone has been associated with a marked decrease in seizure threshold (Moran and Smith, 1998; Smith et al., 1998a).
A similar predisposition to seizures is observed upon abrupt discontinuation of benzodiazepines (File, 1990) and ethanol (Kokka et al., 1993; Reilly et al., 2000).
(3) The spontaneous seizure model. Approach: Unlike previous models that have utilized normal or healthy animals to study neurosteroid withdrawal, this model
was created using chronic epileptic rats to study the impact of neurosteroid withdrawal on spontaneous perimenstrual-like seizures (Reddy and Zeng, 2007). It was
devised again based on the hypothesis that those cyclic episodes of withdrawal would exacerbate seizure occurrence in rats with preexisting epilepsy. Method:
The pilocarpine model was used for inducing chronic epilepsy with spontaneous recurrent seizures. Due to certain reproductive impact of other chronic epilepsy
models, a modified lithium-pilocarpine model was utilized to create a stable epileptic condition with minimal impact on reproductive function (Reddy and Zeng, 2007).
Rats with stable spontaneous seizures were then subjected to repeated pseudopregnancy-finasteride paradigm to model menstruation-like neurosteroid exposure
and withdrawal. Neurosteroid withdrawal was associated with a significant ‘catamenial-like’ exacerbation of spontaneous seizures in epilepsy rats. The withdrawal
period represents a crucial intervention phase for testing of potential treatments, and therefore, this chronic model may be useful for testing novel therapies for the
perimenstrual catamenial epilepsy.
Rat Models
There are rat models of catamenial epilepsy which administer
progesterone by using techniques that range from silastic
implants to administering several daily injections (Costa et al.,
1995; Moran and Smith, 1998; Smith et al., 1998a). These
models simulate the elevated progesterone levels present during
luteal phase. Withdrawal of either the progesterone containing
implants or termination of chronic progesterone treatment
creates a sudden decrease in progesterone (neurosteroids) levels
that could mimic the hormonal milieu of menstruation. The
withdrawal of progesterone has been linked to the marked
decrease in seizure threshold, similar to finasteride-induced NSW
(Moran and Smith, 1998; Smith et al., 1998a). The current rat
models are outlined briefly in Box 1.
In order to improve understanding of the neurobiology of
perimenstrual epilepsy and to investigate possible therapeutics,
we characterized a rodent model designed to imitate the
hormonal changes thought to be involved with perimenstrual
catamenial epilepsy (Reddy et al., 2001). Rodents are the main
mammalian species used in experimental research and have an
estrous cycle that lasts 4–5 days. Because the human menstrual
cycle is 28 days, research based on the fluctuations in seizure
susceptibility during the rodents’ normal estrous cycle do not
result in accurate or relevant data predicted of human disease
(Finn and Gee, 1994). So, the model we present simulates
human hormonal menstrual changes within the rat. The main
criteria for this model is to elevate and prolong the levels of
progesterone and then follow this period of high progesterone
with the removal of hormone to stimulate the reduction in
ovarian secretions which occur during menstruation. A sudden
cessation of progesterone after chronic administration for
3 weeks leads to proconvulsant effects (Smith et al., 1998a,b).
This published protocol is a very basic model of catamenial
epilepsy. Advancing the model is accomplished by creating
“pseudopregnancy” which is more physiologically relevant.
This is done by inducing increased progesterone levels (and
mimicking other changes of hormone levels in the human
luteal phase such as elevated estrogen) by administering
human chorionic gonadotropin and pregnant mare’s serum
gonadotropin at the same time (Figure 2). Pseudopregnancy
in the rat can last 12–13 days, during which estrogen levels
are similar to those in the luteal phase of the human.
Sudden withdrawal of progesterone-derived neurosteroids can
be accomplished by administration of a 5α-reductase inhibitor
which blocks neurosteroid synthesis or by performing an
ovariectomy (Kokate et al., 1999; Reddy and Ramanathan, 2012).
NSW is linked with enhanced susceptibility to seizures (Smith
et al., 1998a,b; Reddy et al., 2001). We suggest that the phase of
increased seizure susceptibility characterizes a model of human
perimenstrual catamenial seizure exacerbations.
The “neurosteroid withdrawal (NSW)” model had previously
only been used in rats that were otherwise normal and
healthy; seizures were induced with pentylenetetrazol. Recently,
this model has been used with female rats with a history
of status epilepticus induced by pilocarpine and ultimately
displayed recurrent seizures spontaneously (Reddy and Zeng,
2007). As demonstrated in the study, these rats showed a
transitory rise in the occurrence of spontaneous seizures
following NSW (Reddy, 2009). Utilizing animals that were
epileptic and spontaneously displaying recurrent seizures, has
better relevancy and authenticity for catamenial epilepsy than
those with acute seizure threshold outcomes. The period of
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FIGURE 2 | Gonadotropin protocol for rat NSW model of catamenial epilepsy. Rats are treated sequentially with gonadotropins for inducing prolonged
elevated serum progesterone levels. On day 11, animals are treated with finasteride, which blocks the conversion of progesterone to the neurosteroid AP, resulting in
“neurosteroid withdrawal.” Acute seizure testing is performed on the day following finasteride administration. For studies of spontaneous seizures, the gonadotropin
treatment was initiated 5 months after pilocarpine-induced epilepsy. Progesterone and AP plasma levels are represented as dashed lines schematically illustrate time
course of the fluctuations in hormone levels (Adapted from Reddy and Rogawski, 2009).
withdrawal represents a crucial intervention phase for the testing
of potential therapeutics. While this approach is possibly more
applicable to human epilepsy, it is considerably more demanding
of personnel and less suited for comprehensive pharmacological
investigations.
Mouse Models
Although rat models are extremely useful for testing new
therapeutic approaches for catamenial epilepsy (Reddy and
Rogawski, 2001), there are also a few mouse models that
recapitulate the neuroendocrine and clinical features of
catamenial epilepsy. Mouse models of catamenial epilepsy
are essential for molecular and genetic investigations. The
current mouse models are outlined briefly in Box 2. Recently,
we developed two distinct mouse models of perimenstrual
catamenial epilepsy (Gangisetty and Reddy, 2010; Reddy et al.,
2012) (Figure 3). These models are based on the rationale that a
decrease in seizure susceptibility occurs when neurosteroid levels
are elevated (luteal phase) and an increase in seizure susceptibility
occurs during the withdrawal period (perimenstrual periods),
which is associated with plasticity changes of the GABA-
A receptor subunits. First, a chronic and recurring seizure
condition is generated using the hippocampus kindling model
in female mice. Second, the fully kindled mice are subjected
to fluctuating levels of neurosteroids, like in the ovarian cycle.
Here, we utilized two distinct pharmacological approaches
to induce elevated neurosteroid levels: (a) chronic exogenous
progesterone treatment protocol, and (b) gonadotropin regimen
for induction of endogenous synthesis. In the first series, mice
were treated with progesterone for 7 days. On the morning of
the 7th day, mice were administered the finasteride to NSW to
model perimenstrual seizures (Figure 3) (Gangisetty and Reddy,
2010).
In the second series, neurosteroid levels were elevated by way
of sequential gonadotropin treatment, which was followed by
finasteride treatment to produce a withdrawal state (Figure 3)
(Reddy et al., 2012). In both approaches, elevated neurosteroid
exposure reduced seizure expression and susceptibility in fully
kindled mice, indicating the protection offered by neurosteroids.
Mice that were fully kindled and exposed to NSW presented
with enhanced seizure susceptibility, elevated intensity and
increased frequency. In pharmacological studies, these mice
also showed enhanced neurosteroid potency and reduced
sensitivity to benzodiazepine, akin to the clinical phenotype.
Changes in seizure susceptibility and responses to antiseizure
drugs are linked to an upregulation of α4- and δ-subunits
of hippocampal GABA-A receptors (Gangisetty and Reddy,
2010; Reddy et al., 2012). The gonadotropin paradigm appears
more physiologically similar than the exogenous pharmacological
progesterone treatment. These mouse models of perimenstrual
catamenial epilepsy can be used in the investigation of
disease pathology and for the development of new treatment
strategies.
These protocols are similar and consistent to the pseudo-
pregnancy model (Reddy and Rogawski, 2001; Reddy et al.,
2001) as well as typical progesterone approaches used
historically for the induction of NSW (Moran and Smith,
1998; Moran et al., 1998; Smith et al., 1998a,b). Although it
is impractical to expect perfect replication of the endocrine
environment of the human cycle in mouse models, these
are physiologically similar to the perimenstrual phase. The
gonadectomy model was not used due to likely difficulty of
interpretation associated with total depletion of ovarian-derived
hormones. Furthermore, the mice would require hormone
replacement after such a procedure, which could have varying
effects on seizures dependent on the age, hormone dose, and
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BOX 2 | Mouse catamenial epilepsy models.
(1) The exogenous progesterone model. Approach: In this model, mice received chronic injections of progesterone and the resulting elevated neurosteroid AP
was abruptly withdrawn by blocking its synthesis from progesterone by administration of finasteride (Omkaram and Reddy, 2010; Carver et al., 2014). Method:
A state of neurosteroid withdrawal was induced in mice by an exogenous progesterone treatment protocol (Figure 3A). To produce prolonged elevated levels of
neurosteroids that more closely model the luteal changes in women, mice were treated with progesterone (25 mg/kg s.c.), twice daily at 9 AM and 6 PM for 7 days.
On the morning of the 7th day, mice were injected with finasteride (50 mg/kg i.p.). Animals were examined 24 h after finasteride (neurosteroid withdrawal, day 8).
Progesterone was administered rather than the neurosteroid AP because it is known that elevated circulating levels of progesterone, such as those found during the
luteal phase, are readily converted to neurosteroids in the brain regions that express neurosteroid synthesizing enzymes (Figure 3A). The progesterone administration
protocol results in a high physiological concentration of AP in plasma, and an acute withdrawal was evident by a nearly complete decline in AP within 24 h after
finasteride (Figure 3A). This neuroendocrine manipulation was implemented in fully-kindled mice. Mice were stimulated until they had exhibited stage 5 seizures and
then they were subjected to neurosteroid withdrawal. Changes in seizure activity during neurosteroid withdrawal in mice in the hippocampus kindling model. There
was a decreased threshold to induce generalized seizures, increased seizure duration, and time-course of the percent of animals exhibiting generalized seizures (stage
4/5) at 50% of regular ADT current. This augmented seizure susceptibility is an index of perimenstrual-like seizure exacerbation.
(2) The gonadotropin model. Approach: In this model, fully-kindled mice exhibiting a stable stage 5 seizures were utilized to better simulate a perimenstrual-like
seizure condition (Reddy et al., 2012). Mice received a regimen of gonadotropins to elevate the endogenous neurosteroids, and then were drastically reduced with the
administration of finasteride. It is based on the premise that steady physiological levels of elevated neurosteroid more closely resemble that of the neuroendocrine milieu
of perimenstrual period. Method: A state of elevated neurosteroid was induced in female mice by a sequential gonadotropin regimen (Brooke et al., 2007). To produce
prolonged elevated levels of progesterone and neurosteroids that more closely model the luteal changes in women, mice were treated with pregnant mare’s serum
gonadotropin (5 IU, s.c.) at 3 PM followed 48 h later by human chorionic gonadotropin (5 IU, s.c.) at 1 PM (Figure 3B). The day of the second gonadotropin injection
was considered day 1 of elevated neurosteroids. On the morning of the 9th day, mice were injected with finasteride (50 mg/kg, i.p.) to produce an abrupt decline
in neurosteroid levels to more closely model perimenstrual changes in women. Animals were tested 24 h after finasteride administration (neurosteroid withdrawal).
The gonadotropin administration protocol resulted in high circulating levels of AP, and an acute withdrawal was evident by a significant decline in AP 24 h after
finasteride administration (Figure 3B). Elevated neurosteroid exposure reduced seizure expression in fully kindled mice. Fully-kindled mice subjected to neurosteroid
withdrawal showed increased generalized seizure frequency and intensity and enhanced seizure susceptibility. They also showed reduced benzodiazepine sensitivity
and enhanced neurosteroid potency, similar to the clinical catamenial seizure phenotype.
duration of treatment (Scharfman et al., 2005; Shen et al.,
2010).
RELEVANCY AND VALIDATION OF
EXPERIMENTAL MODELS
There are many advantages to using rodents, particularly mice
and rats, as models in epilepsy research. The anatomic and
physiologic similarities between humans and rodents make the
small rodents the most widely used animal model for a variety
of seizure disorders. Most studies of acute seizures and chronic
epilepsy induced by chemoconvulsants have been carried out in
rats and mice. The short generation time, relatively small size, and
accelerated life span of rats and mice help maintain efficient space
and time periods, which allows performance of a manageable
study. Furthermore, most behavioral seizure scoring systems have
been developed and validated in rats and mice; hundreds of
transgenic mice are available, allowing researchers to investigate
how specific genes function in epilepsy. Specifically as it relates to
the field of perimenstrual seizures, the sensitivity of rats and mice
to different anticonvulsants closely resembles that of humans. For
example, the lower efficacy of diazepam and valproate to protect
against perimenstrual seizures in rat models is similar to clinical
reports (Reddy and Rogawski, 2000b).
In order for animal models of catamenial epilepsy to be
validated, they are required to display certain criteria and
be representative of the human condition (Reddy, 2009).
Furthermore, the models should have the ability to elicit a
similar epilepsy-like state as well as a pathophysiology that
mirrors the disease in humans (Table 1). The NSW model
meets many of these criteria and certainly offers advantages
over the use of conventional seizure models (Reddy, 2009).
The models of catamenial epilepsy previously described are
based on similar physiological dynamics of ovarian progesterone
secretion during the menstrual cycle, which cannot be simulated
in the exogenous drug delivery models. In pseudopregnancy,
secretion of progesterone by the luteinized ovaries occurs in a
physiologically appropriate episodic fashion and leads to plasma
progesterone levels that are within the normal physiologic range.
Additionally, the 9 days elevation of progesterone and AP levels
seen in the rodent model closely matches the 10 days increase
in AP levels during the luteal phase of humans. Even though the
exact mechanisms and etiology of catamenial epilepsy are not
wholly understood, the NSW model simulates the AP-to-estrogen
ratio changes that are believed to be critical in perimenstrual
catamenial epilepsy. Female rats with spontaneous recurrent
seizures are more appropriate to model catamenial epilepsy.
There are some difficulties in this, such as controlling a consistent
induction of epileptogenesis in female rats as well as potential
abnormities in maintaining regular estrous cycles (Amado and
Cavalheiro, 1998). Moreover, it is important to note that the
actual endocrine conditions that exist in the human menstrual
cycle are different from those observed in animal models of
catamenial epilepsy; the estrous cycle duration in most rodents is
approximately 4–7 days, and the menstrual cycle in women lasts
about 28 days.
Catamenial seizures are often seen in women diagnosed
with epilepsy; therefore, research models should also utilize
animal with preexisting epilepsy. “Kindling” is an appropriate
background paradigm for characterizing a perimenstrual
catamenial epilepsy model. Hippocampus kindling is commonly
used as a model of human complex partial seizures. In contrast
to pilocarpine-induced epilepsy, the kindling model will not
result in neuronal loss and preserves the reproductive capability
in the rodent. Using the NSW paradigm, we developed a
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FIGURE 3 | Mouse NSW models of catamenial epilepsy. (A) In the exogenous protocol, progesterone was administered twice daily for 7 d, and finasteride was
administered on the final day, resulting in NSW. Data collections were done 24 h after induction of withdrawal (day 8). The resulting plasma levels of AP were
estimated at day 8 in mice following treatment with vehicle (β-cyclodextrin solution), progesterone (P), and P + finasteride (NSW). Each bar represents the
mean ± SEM (n = 6 mice per group). ∗p < 0.01 vs. vehicle; #p < 0.01 vs. P-treatment group (Adapted from Carver et al., 2014). (B) In the gonadotropin-based
protocol, fully kindled mice were treated with pregnant mare’s serum gonadotropin (PMSG, 5 IU, s.c.) at 3 PM followed 48 h later human chorionic gonadotropin
(HCG, 5 IU, s.c.) at 1 PM. Then, on day 9 they were given finasteride (50 mg/kg, i.p.). Plasma AP levels were estimated in mice following treatment with
gonadotropins and finasteride (50 mg/kg, i.p.) paradigm for induction of neurosteroid withdrawal (NSW). The dramatic decline in neurosteroid levels 24 h after
finasteride would create a state of NSW (Adapted from Reddy et al., 2012).
mouse kindling model and successfully utilized it to test new
drugs/therapeutics that prevent kindled catamenial seizures
(Reddy et al., 2012). The gonadotropin-induced endocrine state
is more physiologically similar to the hormonal milieu of the
menstrual cycle than the paradigms that employ exogenous
progesterone or AP treatment (Shen et al., 2005; Gangisetty
and Reddy, 2010). It is hypothesized that local production of
neurosteroids happens in areas of the brain like the hippocampus
and amygdala because these are germane to epilepsy (Reddy,
2013c). Seizure exacerbation observed in these models is due to
the reduction of neurosteroids in the brain. Consequently, NSW
associated with increased exacerbation of seizures might signify
a transitory surrogate marker for perimenstrual catamenial
epilepsy.
Non-rodent species, particularly canines, hold a unique
advantage over rodents because epilepsy is a natural disease in
some dogs (Patterson, 2014; Packer and Volk, 2015). In fact,
epilepsy is the most common neurologic disease in dogs and is
considered to have a genetic basis in many of its forms (Ekenstedt
and Oberbauer, 2013). Undoubtedly, canines have a number of
advantages. Since the 1970s dogs have been used as a limited
comparative model, particularly in the areas of drug therapy,
dietary therapy, and other therapeutic devices for epilepsy. The
idiopathic epilepsy appears similar between humans and canines;
therefore dogs represent the most appropriate animal model
of epilepsy. However, canines may not be the best model for
catamenial epilepsy. Striking ovarian cycling differences exist
in dogs, including variable or long interestrus period, making
it difficult to study catamenial seizures in female dogs (Reddy
and Gadsby, 2009). Pseudopregnancy is common which could
provide a model system for neuroendocrine studies, but there
are ethical issues related to the use of dogs that precludes
using female dogs as a model for catamenial epilepsy. Thus, the
rodent model is preferable to the canine model when studying
perimenstrual seizures.
DISCOVERY OF AN EXTRASYNAPTIC
MECHANISM FOR TARGETED THERAPY
OF CATAMENIAL EPIELPSY
Neuronal homeostatic systems may regulate the net impact
of neuroendocrine factors on neuronal excitability. The
GABA-A receptor is a pivotal chloride ionophore for fast
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FIGURE 4 | Extrasynaptic GABA-A receptor plasticity during the
ovarian cycle: A perimenstrual delta force mechanism for neurosteroid
sensitivity. During the luteal phase, extrasynaptic δGABA-A receptors in the
dentate gyrus contribute to tonic inhibitory currents to relatively elevate the
levels of progesterone-derived neurosteroids. At perimenstrual period,
neurosteroid levels decline abruptly creating a state of withdrawal. This may
trigger the neuronal homeostatic response to increase the δGABA-A receptor
abundance to respond to very low levels of neurosteroids, in order to restore
tonic currents during the transient withdrawal period.
inhibitory transmission in the limbic regions relevant to epilepsy
pathology. Synaptic γ2-GABA-A receptors mediate the phasic
inhibitory currents in response to vesicular release of GABA.
They are sensitive to benzodiazepines and neurosteroids.
Extrasynaptic δ-GABA-A receptors mediate the tonic inhibitory
currents in response to extracellular GABA and play a key
role in network excitability (Brickley and Mody, 2012).
These extrasynaptic receptors are extremely insensitive
to benzodiazepines and highly sensitive to neurosteroids
(Carver and Reddy, 2013). Hence, GABA-A receptor plasticity
could have an important part to play in the pathophysiology
of catamenial epilepsy (Reddy, 2009, 2013a). In 2000, we
unexpectedly discovered that neurosteroids, including AP
and synthetic analogs such as ganaxolone, showed enhanced
anticonvulsant activity in the catamenial epilepsy model
(Reddy and Rogawski, 2000b, 2001). Although the model
was created based on the NSW paradigm, the molecular
mechanism behind neurosteroid’s seizure protection in the
catamenial model remained poorly understood. This seminal
discovery led us to propose a neurosteroid replacement therapy
for prevention of catamenial seizures (Reddy and Rogawski,
2009; Reddy, 2013a). Subsequently we conducted a large
array of studies during the past decade to investigate such
molecular mechanisms, including progesterone receptors,
Egr-3 pathway, and GABA receptor subunit plasticity
(Reddy, 2004, 2009, 2013a,b, 2014; Reddy et al., 2004, 2010,
2012; Reddy and Zeng, 2007; Gangisetty and Reddy, 2010;
Reddy and Mohan, 2011; Reddy and Ramanathan, 2012).
Our most recent studies have ultimately culminated in the
discovery of an extrasynaptic mechanism of catamenial
epilepsy, one underlying the neurosteroid sensitivity in NSW
paradigms (Reddy et al., 2012; Wu et al., 2013; Carver et al.,
2014).
The application of multidisciplinary approaches has enabled
us to uncover the unique plasticity of extrasynaptic δ GABA-A
receptors in the dentate gyrus in a mouse model of perimenstrual
catamenial epilepsy (Carver et al., 2014). The hippocampal
δGABA-A receptors experience plasticity during the menstrual
cycle, pregnancy, and parturition (Maguire et al., 2005; Maguire
and Mody, 2007; Reddy, 2009; Wu et al., 2013). Hence, we
utilized a mouse model of exogenous progesterone/NSW to
characterize the GABA-A receptor subunit expression profile in
the hippocampus (Gangisetty and Reddy, 2010). We additionally
expanded our studies to a mouse gonadotropin/NSW model of
catamenial epilepsy (Reddy et al., 2012). In both models, we
found a striking increase in the GABA-A receptor δ-subunit,
a common partner of α4 in extrasynaptic GABA-A receptors
in the dentate gyrus. It is likely that extrasynaptic δGABA-A
receptors may endure cyclical plasticity in response to natural
fluctuation of hormones during the ovarian cycle and hormone
withdrawal period (Figure 4). This notion is also supported by
the ovarian cycle-related plasticity and function of δGABA-A
receptors in the dentate gyrus (Wu et al., 2013). Finally, our
electrophysiological studies convincingly demonstrated that the
increased expression of the δGABA-A receptors is functionally
significant for enhanced AP potentiation of tonic currents in
the NSW model (Carver et al., 2014). At the same time, we
found smaller tonic GABA current shifts in NSW granule cells
compared to controls in the absence of added GABA, indicating
low extracellular GABA and other relevant changes in NSW
hippocampus. Therefore, the catamenial experimental model is
a classical illustration that that the pathogenic origin is due to a
rapid shift in tonic current balance in the dentate gyrus, rather
than a specific range of AP levels. Dentate granule cells are well
known as gatekeepers of seizure propagation to the hippocampus,
which explains the observed effects of NSW and AP on seizure
susceptibility.
In essence, our studies show that perimenstrual up-regulation
of extrasynaptic δGABA-A receptors mediates tonic inhibition
in the dentate gyrus granule cells and confers enhanced
sensitivity to neurosteroids (Figure 4). However, such selective
overexpression of δGABA-A receptors is not sufficient to
suppress the increased seizure susceptibility triggered by NSW
in the absence of AP. Yet, this pathologic increase in δGABA-
A receptors may act as a vehicle-catalyst (“Trojan horse”)
for the exogenous AP to inhibit seizures (Galanopoulou,
2015). Indeed, this special sensitivity to AP that women with
perimenstrual epilepsy exhibit is in agreement with the findings
from the NIH progesterone trial, in which the responder
group was women with C1 catamenial epilepsy (Herzog et al.,
2012). Interestingly, these women responders demonstrated
significant posttreatment increase in AP levels (Herzog et al.,
2014). Therefore, neurosteroid replacement therapy, proposed
earlier, is an ideal therapeutic strategy for C1 catamenial
epilepsy (Reddy and Rogawski, 2009; Reddy, 2014). Synthetic
neurosteroids given as a brief pulse treatment protocol during
this perimenstrual period may be effective in preventing or
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reducing catamenial seizures. Continuing neurosteroid therapy
throughout the menstrual cycle at low doses would contribute
little anticonvulsant activity, but would allow patients to avoid
negative sedative effects if they are prone to experiencing them.
Under both strategies, neurosteroids might provide an effective
approach for catamenial epilepsy therapy (Reddy, 2013a). Thus,
the cyclical plasticity of an extrasynaptic δGABA-A receptors
may serve as lead target for neurosteroid therapy of catamenial
epilepsy.
CONCLUSION AND FUTURE
PROSPECTS
Catamenial epilepsy is a complex neuroendocrine condition
of refractory menstrual seizures (El-Khayat et al., 2008;
Tuveri et al., 2008; Herzog et al., 2014). Neurosteroids are
involved in the pathophysiology of catamenial epilepsy.
Perimenstrual catamenial (C1) epilepsy is thought to be caused
in part by the withdrawal of neuroprotective neurosteroids
resulting from the decrease of progesterone levels during the
menstrual cycle. There are currently no specific treatments for
catamenial seizures; therefore, the NSW model of catamenial
epilepsy has been utilized to study treatments for catamenial
epilepsy. One important observation is that traditional AEDs
have lower efficacy to catamenial seizures. This finding is
consistent with women with catamenial epilepsy, who do
not respond to these drugs. The model therefore represents
a form of the pharmacoresistance paradigm. The higher
relative expression of benzodiazepine-insensitive GABA-A
receptors during NSW probably explains the reduced activity
of benzodiazepines. We found that neurosteroids had enhanced
activity in the perimenstrual catamenial epilepsy model.
Based on our studies in catamenial epilepsy models, we
suggest that “neurosteroid replacement” may be an effective
approach to prevent seizure exacerbations often seen with
around the menstrual cycles of women. A neurosteroid
or a neurosteroid-like drug such as ganaxolone could be
given in a “pulse” before menstruation and then either
continuously administered at a low dose throughout the
month at low doses or discontinued, so as to avoid possible
sedative side effects (Reddy, 2014). Therefore, neurosteroids
might provide an effective approach for catamenial epilepsy
therapy.
The molecular mechanisms underlying the enhanced
neurosteroid sensitivity have been reported in mouse models.
In a recent publication, we reported the unique plasticity of
extrasynaptic δGABA-A receptors in the dentate gyrus of the
hippocampus using a mouse perimenstrual model (Reddy
et al., 2012; Wu et al., 2013; Carver et al., 2014). A delta-
force hypothesis was coined to explain this phenomenon
(Galanopoulou, 2015). In summary, the proposed mechanism
poses that the perimenstrual decline in neurosteroids triggers the
selective overexpression of δGABA-A receptors in the dentate
gyrus granule cells, but this is not sufficient to suppress the
increased seizure susceptibility of NSW mice in the absence
of AP (Figure 4). Nevertheless, this compensatory increase
in δGABA-A receptors may act as a “Trojan horse” for the
exogenous neurosteroid to inhibit seizures. Indeed, this special
sensitivity to neurosteroids which women with perimenstrual
epilepsy exhibit is in agreement with the findings from the
NIH progesterone trial, in which the responder group was
women with the perimenstrual type catamenial epilepsy (Herzog
et al., 2012). Therefore, the extrasynaptic mechanism represents
a molecular rationale for neurosteroid therapy of catamenial
epilepsy. Synthetic neurosteroids that enhance tonic inhibition
are suitable lead candidates for clinical studies (Carver and
Reddy, 2016).
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